



ZELTIA NET SALES INCREASED BY 23% TO €105 MILLION

The biopharmaceutical sector represents 32% of the turnover according to net sales, compared to 12% of previous year

Madrid, February 26, 2009: Zeltia Group's net sales (ZEL.MC) increased 23% last year to reach €105 million, as announced by the company during the presentation of interim results for the year 2008.

The Group's Investment in R&D was 57.5 million Euros in 2007, 11% more than in 2007. EBITDA improved by 23% over the previous year. Net sales of the biopharmaceutical sector represent 32% of the total sales, compared with 12% in 2007.

The available cash minus the short-term debt amounted to 38.4 million. The Group confirms its cash position ensures they have sufficient funds to achieve their investment objectives, until the potential approval of Yondelis for the treatment of ovarian cancer is confirmed.

PharmaMar, a biotechnology company leading the research, development and commercialization of anti-cancer drugs of marine origin, has exceeded 30 million€ gross sales of Yondelis. In 2008, PharmaMar advanced the clinical development of its anticancer product portfolio; Aplidin, Irvalec, Zalypsis. Yondelis is also being further developed for new indications. In the last financial year the registration of the drug for ovarian cancer refractory was presented to health authorities.

Genomica, a company specializing in forensic genetics and clinical diagnosis, closed the year with an increase in its turnover by 33% compared to 2007 for the second consecutive year. Domestic sales increased by 49% and exports increased by 37%.

Noscira, a company specializing in the development of drugs for neurodegenerative diseases, initiated Phase II studies of clinical development of NP-12 in patients with Alzheimer's disease. NP-12 is a novel compound, with an innovative mechanism of action. It is in 2009 scheduled to start its clinical development for the treatment of Progressive Supranuclear Palsy.

Xylazel's net result was increased by 28.5% in 2007. The company has launched new eco-friendly products that represented 4% of the annual sales. The company has initiated an innovative project for the application of nanotechnology as an environmentally friendly alternative for the preservation of wood.

Copyr Zelnova and its subsidiary continue a successful export strategy of their product for organic farming.

About Zeltia:

Zeltia S.A. Biotech is a pioneer Biotech Group, leader in Spain and sixth European Group by market capitalization. Zeltia Group is composed by following companies: **PharmaMar**, the leading global biotechnology company dedicated to advancing cancer treatment through the discovery and development of innovative marine-derived medicines; **Noscira**, a biotech company focused on the discovery and development of new drugs against Alzheimer's and other neurodegenerative diseases of the nervous system; **Genomica**, first Spanish company in the field of molecular diagnostics; **Sylentis**, an innovative company dedicated to the research of therapeutic applications of gene silencing (RNAi) technology; **Zelnova & Xylazel** highly profitable two companies, leaders in their market segments.

For more information:

Capital Markets (tel. +34 91 444 45 00)
Alfonso Hurtado de Mendoza
Florence Radizza

Media Relations (tel. +34 91 846 60 00)
Fernando Mugarza
Carlos Martinez de la Serna
Carolina Lanzas Otazu

This press release is also available in "Press Office" area at www.zeltia.com